Final five-year results of the REMEDEE Registry: Real-world experience with the dual-therapy COMBO stent

Laura S. M. Kerkmeijer, Jaya Chandrasekhar, Deborah N. Kalkman, Pier Woudstra, Ian B. A. Menown, Harry Suryapranata, Peter den Heijer, Andrés Iñiguez, Arnoud W. J. van 't Hof, Andrejs Erglis, Karin E. Arkenbout, Philippe Muller, Karel T. Koch, Jan G. Tijssen, Marcel A. M. Beijk, Robbert J. de Winter

Research output: Contribution to JournalArticleAcademicpeer-review

1 Citation (Scopus)

Abstract

Objectives: This final report from the REMEDEE Registry assessed the long-term safety and efficacy of the dual-therapy COMBO stent in a large unselected patient population. Background: The bio-engineered COMBO stent (OrbusNeich Medical BV, The Netherlands) is a dual-therapy pro-healing stent. Data of long-term safety and efficacy of the this stent is lacking. Methods: The prospective, multicenter, investigator-initiated REMEDEE Registry evaluated clinical outcomes after COMBO stent implantation in daily clinical practice. One thousand patients were enrolled between June 2013 and March 2014. Results: Five-year follow-up data were obtained in 97.2% of patients. At 5-years, target lesion failure (TLF) (composite of cardiac death, target-vessel myocardial infarction, or target lesion revascularization) was present in 145 patients (14.8%). Definite or probable stent thrombosis (ST) occurred in 0.9%, with no additional case beyond 3-years of follow-up. In males, 5-year TLF-rate was 15.6 versus 12.6% in females (p =.22). Patients without diabetes mellitus (DM) had TLF-rate of 11.4%, noninsulin-treated DM 22.7% (p =.001) and insulin-treated DM 41.2% (p <.001). Patients presenting with non-ST segment elevation acute coronary syndrome (NSTE-ACS) had higher incidence of TLF compared to non-ACS (20.4 vs. 13.3%; p =.008), while incidence with STE-ACS was comparable to non-ACS (10.7 vs. 13.3%; p =.43). Conclusion: Percutaneous coronary intervention with the dual-therapy COMBO stent in unselected patient population shows low rates of TLF and ST to 5 years. Remarkably, no case of ST was noted beyond 3 years.

Original languageEnglish
Pages (from-to)503-510
Number of pages8
JournalCatheterization and cardiovascular interventions
Volume98
Issue number3
Early online date2020
DOIs
Publication statusPublished - Sep 2021

Keywords

  • drug-eluting stent
  • dual-therapy stent
  • percutaneous coronary intervention

Cite this